Spots Global Cancer Trial Database for her2 negative breast carcinoma

Every month we try and update this database with for her2 negative breast carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs	NCT06176261	Breast Cancer Breast Cancer F... Metastatic Trip... ER Positive Bre... HER2-negative B... HER2 Negative B... ER-negative Bre...	Datopotamab Der...	18 Years -	Dana-Farber Cancer Institute
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy	NCT04379570	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... HER2 Negative B... Hormone Recepto... Invasive Breast... Prognostic Stag... Prognostic Stag... Prognostic Stag...	Educational Int... Text Message-ba... Motivational In... Best Practice Questionnaire A... Quality-of-Life...	18 Years -	Alliance for Clinical Trials in Oncology
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer	NCT06016738	Breast Cancer Advanced Breast... Metastatic Brea... ER Positive Bre... HER2 Negative B...	Palazestrant Fulvestrant Anastrozole Letrozole Exemestane	18 Years -	Olema Pharmaceuticals, Inc.
Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery	NCT05327608	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Ductal C... HER2 Negative B... Hormone Recepto... Invasive Breast...	Short-Term Fast...	18 Years -	Thomas Jefferson University
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy	NCT04379570	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... HER2 Negative B... Hormone Recepto... Invasive Breast... Prognostic Stag... Prognostic Stag... Prognostic Stag...	Educational Int... Text Message-ba... Motivational In... Best Practice Questionnaire A... Quality-of-Life...	18 Years -	Alliance for Clinical Trials in Oncology
Intermittent Fasting for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery	NCT05327608	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Ductal C... HER2 Negative B... Hormone Recepto... Invasive Breast...	Short-Term Fast...	18 Years -	Thomas Jefferson University
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer	NCT06016738	Breast Cancer Advanced Breast... Metastatic Brea... ER Positive Bre... HER2 Negative B...	Palazestrant Fulvestrant Anastrozole Letrozole Exemestane	18 Years -	Olema Pharmaceuticals, Inc.
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer	NCT02157051	HER2 Negative B... Recurrent Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage III Breas...	CD105/Yb-1/SOX2... Laboratory Biom...	18 Years -	University of Washington

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: